Daisuke Sakai

10PUBLICATIONS
56CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markersLivestock cloning
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 06, 2025
Multi-Regional Profiling of Epidermal Growth Factor Receptor L858R Mutation-Positive Metastatic Renal Pelvic Cancer Successfully Treated With Osimertinib.

Yoshiyuki Yamamoto, Atsushi Kuwahara, Atsunari Kawashima

|May 23, 2025
Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial.

Daisuke Sakai, Shigenori Kadowaki, Ryohei Kawabata

|Aug 01, 2024
Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial.

Masataka Yagisawa, Hiroya Taniguchi, Taroh Satoh

|Nov 15, 2022
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.

Kensei Yamaguchi, Yung-Jue Bang, Satoru Iwasa

|Apr 30, 2022
Real-world effectiveness of third- or later-line treatment in Japanese patients with HER2-positive, unresectable, recurrent or metastatic gastric cancer: a retrospective observational study.

Daisuke Sakai, Takeshi Omori, Soichi Fumita

|Oct 26, 2020
Impact of sarcopenia in patients with advanced or recurrent colorectal cancer treated with regorafenib.

Yasushi Murachi, Daisuke Sakai, Jun Koseki

Pageof 2

Frequent Collaborators

3 joint publications

Taroh Satoh

2 joint publications

Shigenori Kadowaki

2 joint publications

Hisato Kawakami

1 joint publications

Eiichi Morii